MERCK KGAA O.N.
Commented by Armin Schulz on October 16th, 2025 | 07:20 CEST
Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology
In the biotech sector, a single technology can often determine success or failure. Canadian-German company BioNxt Solutions is taking a different approach, relying on three pillars, each targeting major markets and advancing established blockbusters from leading pharmaceutical companies. October has already brought decisive progress, from accelerated patent protection to concrete milestones in development. These concentrated positive signals show that BioNxt Solutions not only has a promising concept, but also the strategy and operational strength to turn it into value. A closer analysis is worthwhile.
ReadCommented by Nico Popp on September 15th, 2025 | 07:15 CEST
No more diet injections! Innovations in weight loss drugs: BioNxt Solutions, Merck & Co., Novo Nordisk
As recently reported by the United Nations Children's Fund (UNICEF), for the first time, more children worldwide are obese than underweight. While this is a great success in the fight against hunger, it also poses new risks. Severe overweight in childhood leads to obesity and associated diseases in adulthood, such as cardiovascular problems and diabetes. The treatment of overweight and diabetes in children is therefore likely to play an even more significant role in the future. GLP-1 receptor agonists have been popular for several years now in the form of modern weight loss injections. With patents expiring soon, experts anticipate substantial further growth and development in this rapidly expanding market. We explain who could benefit and what the future holds for modern diet medications.
ReadCommented by Armin Schulz on July 28th, 2025 | 07:00 CEST
War, raw material shortages, cancer: Capitalize on megatrends with Rheinmetall, Antimony Resources, Merck KGaA
Three megatrends are expected to drive global markets in 2025. Revolutionary technologies, such as AI and cybersecurity, are fundamentally changing the defence sector. At the same time, demand for critical raw materials for defense, high-tech applications, and the energy transition is exploding, requiring new, sustainable supply chains. In parallel, the pharmaceutical industry is undergoing a dramatic shift due to advances in AI-driven research and intensified competition. These forces are shaping the future opportunities for companies. Those who are strategically positioned here will win, as key players Rheinmetall, Antimony Resources, and Merck KGaA demonstrate.
ReadCommented by Nico Popp on July 10th, 2025 | 07:25 CEST
Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark
When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.
ReadCommented by Nico Popp on May 13th, 2025 | 07:10 CEST
The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma
Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.
ReadCommented by Stefan Feulner on April 28th, 2025 | 11:20 CEST
BioNTech, BioNxt, Merck KGaA – Opportunities after the correction
The reporting season for the first quarter of 2025 is underway, and due to US President Donald Trump's tariff hammer, it is more exciting than ever. Investors are likely to focus primarily on forecasts for the rest of the fiscal year. Internet giant Google posted impressive figures last week and is standing firm against looming trade conflicts and antitrust proceedings. Several companies in the biotech sector also had news to report and offer attractive entry opportunities at reduced prices.
ReadCommented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
ReadCommented by Stefan Feulner on March 4th, 2022 | 13:33 CET
Bayer, Defence Therapeutics, Merck KGaA - At the start of the trend
The biotech industry is the innovative engine for a pharmaceutical industry dependent on new concepts due to the shift from blockbuster products to personalized medicine. Even before Corona, more than EUR seven billion per year was invested in R&D in 2019. The development of new drugs is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs is expiring or has already expired. For this reason, the pharmaceutical industry is now much more often entering biotech companies in the early development phases of a new drug. The example of vaccine manufacturers has successfully highlighted this strategy, which will also be applied to other diseases in the future.
ReadCommented by Carsten Mainitz on December 9th, 2021 | 04:57 CET
Barrick Gold, Barsele Minerals, Merck KGaA - Much movement in the market
Currently, there is little movement in the gold market. The gold price peaked at around USD 2,070 an ounce in the summer of last year, and it is now consolidating around USD 1,800. Investors prefer to invest in higher-yielding assets such as equities or cryptocurrencies despite the economic environment with high inflation and historically low-interest rates. Behind the scenes, however, a lot is going on in the gold market. Most recently, for example, Tembo Gold announced its entry by Barrick Gold, with further acquisitions to follow.
ReadCommented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read








